Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA PHAR Form 4 June 11, 2013	MACEUTIC	CALS INC									
FORM 4	1									PPROVA	۹L
	UNITED	STATES		RITIES A			IGE	COMMISSIO	N OMB Number:	3235-	-0287
Check this bo if no longer subject to Section 16. Form 4 or		/IENT OI	F CHAN	NGES IN SECUI		FICIAI	LOV	VNERSHIP OF	Estimated burden hou	Estimated average burden hours per	
Form 5 Filed pursuant to Section 16(a) of the Securities Section 17(a) of the Public Utility Holding Compa Sec Instruction 1(b).								of 1935 or Secti			0.5
(Print or Type Respo	onses)										
1. Name and Address of Reporting Person <u>*</u> Hacksell Uli			2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer			
		ACADIA PHARMACEUTICALS INC [ACAD]					(Check all applicable)				
(Last) (First) (Middle) 3911 SORRENTO VALLEY BLVD.			3. Date of Earliest Transaction (Month/Day/Year) 06/07/2013				Director 10% Owner Officer (give title Other (specify below) below) CEO				
	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
SAN DIEGO, C	CA 92121							Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivativ	e Securit	ties A	cquired, Disposed	of, or Beneficia	lly Owne	d
	2. Transaction Date 2A. Dec (Month/Day/Year) Executi any (Month		Date, if	Code	nAcquire Dispose	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	al iip
				Code V	Amount	or (D) F	Price	(Instr. 3 and 4)			
Reminder: Report o	n a separate line	e for each cla	ass of sec	urities bene	ficially ov	vned dire	ctly o	r indirectly.			
					Pers infor requ	ons who mation ired to r lays a cu	o res conta respo	pond to the colle ained in this forn and unless the fo atly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date 3A	A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year) Ex	execution Date, if	Transactic	Derivative	Expiration Date	Underlying Securities
Security	or Exercise	an	ny	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed o (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 17.01	06/07/2013		А		300,000		(1)	06/06/2023	Common Stock	300,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Hacksell Uli 3911 SORRENTO VALLEY BLVD. SAN DIEGO, CA 92121			CEO				

Signatures

/s/ Uli Hacksell 06/11/2013

**Signature of

Date

Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 25% of the shares subject to the Stock Option vest and become exercisable on June 7, 2014. The remaining shares vest and become (1) exercisable thereafter in 36 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.